Ambu A/S Unsponsored ADR (OTCMKTS:AMBBY – Get Free Report) was the target of a significant increase in short interest in the month of September. As of September 15th, there was short interest totaling 92 shares, an increase of 253.8% from the August 31st total of 26 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily volume of 74 shares, the short-interest ratio is presently 1.2 days.
Wall Street Analyst Weigh In
Separately, UBS Group downgraded shares of Ambu A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 15th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, the stock has a consensus rating of “Hold”.
View Our Latest Research Report on Ambu A/S
Ambu A/S Price Performance
Ambu A/S (OTCMKTS:AMBBY – Get Free Report) last posted its quarterly earnings results on Tuesday, August 25th. The company reported $0.09 earnings per share for the quarter. The business had revenue of $255.12 million for the quarter. Ambu A/S had a net margin of 8.18% and a return on equity of 8.49%.
Ambu A/S Company Profile
Ambu A/S is a Danish medical technology company that develops, manufactures and markets single-use devices for hospitals and other healthcare providers. The company focuses on reducing the need to reprocess reusable equipment while supporting clinical procedures in areas such as endoscopy, anesthesia and patient monitoring.
Ambu’s product portfolio includes disposable endoscopes and related visualization systems, airway management products, anesthesia equipment and devices used for patient monitoring and diagnostics.
Featured Stories
- Five stocks we like better than Ambu A/S
- Data Centers Got the AI Hype—But Office REITs May Get the Rent Hikes
- 2 Cybersecurity Stocks Breaking Out as AI Continues to Be a Tailwind
- 3 More AI Infrastructure Plays Beyond the Big Names
- CAVA Stock Slips: Sector Fear or Valuation Reality?
Receive News & Ratings for Ambu A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambu A/S and related companies with MarketBeat.com's FREE daily email newsletter.
